Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(17s)-17-(((dimethoxyphosphoryl)methoxy)carbonyl)-3β-hydroxy-28-norolean-12(13)-ene is a semisynthetic pentacyclic triterpenoid derivative of oleanolic acid. It features a dimethylphosphonate moiety attached via a methoxycarbonyl linker at the C17 position, a modification designed to improve the pharmacokinetic properties and biological activity of the parent triterpene. Research indicates that this compound possesses significant antiproliferative activity against melanoma cells, specifically the B164A5 line, where it induces apoptosis as evidenced by nuclear condensation. Unlike some cytotoxic agents, it does not appear to cause significant membrane damage (as measured by LDH release) or vascular toxicity in HET-CAM models, suggesting a targeted mechanism of action suitable for further oncological investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (17s)-17-(((dimethoxyphosphoryl)methoxy)carbonyl)-3β-hydroxy-28-norolean-12(13)-ene.